Comparison of the safety profile of [ 177 Lu] Lu-DOTATATE between the NETTER-1 and NETTER-2 trials and pharmacovigilance data from EudraVigilance and FAERS (EANM 2026) - Sep 29, 2026 - Abstract #EP-0875; "Although the overall safety profile of [177Lu]Lu-DOTA-TATE is consistent between clinical trials and pharmacovigilance data, significant differences in the distribution of ADRs by SOC were observed. No new safety signals were identified, and the findings reinforce the need for continuous monitoring in clinical practice."
Adverse events • Clinical • Gastroenterology • Gastrointestinal Disorder • Hepatology
|
|
A. Blesa Jimenez 1; L. Camacho Berné 1; M. Bravo-Ferrer Moreno 2; N. Pérez Castro 1; V. Lopez Prior 1; A. Tembl Ferrairo 1
|